Sugi Predict

Sugi Predict / Compounds / SCHEMBL5526013

SCHEMBL5526013

SCHEMBL5526013

Cc1c(O)ccc2c1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@H](O)CC[C@@H]12

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 9/20 0.82
▸ ESR2 Q92731 8/20 0.82
▸ LMNA P02545 4/20 0.82
▸ MEN1 O00255 3/20 0.82
▸ MAPT P10636 3/20 0.82
▸ KMT2A Q03164 3/20 0.82
▸ KDM4E B2RXH2 2/20 0.82
▸ GAA P10253 2/20 0.82
▸ G6PD P11413 2/20 0.82
▸ PKM P14618 2/20 0.82
▸ MAPK1 P28482 2/20 0.82
▸ MPI P34949 1/20 0.82
▸ CYP19A1 P11511 4/20 0.77
▸ STS P08842 2/20 0.71
▸ HSD17B10 Q99714 3/20 0.63
▸ TSHR P16473 2/20 0.63
▸ CYP1A2 P05177 1/20 0.63
▸ CYP2C9 P11712 1/20 0.63
▸ CYP2C19 P33261 1/20 0.63
▸ HIF1A Q16665 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5526011 1.00 ESR1 (0.82) ESR1ESR2LMNAMEN1MAPT
SCHEMBL224398 0.90 ESR1 (1.00) ESR1ESR2LMNAMEN1MAPT
SCHEMBL29506781 0.90 ESR1 (1.00) ESR1ESR2LMNAMEN1MAPT
SCHEMBL13123059 0.90 ESR1 (1.00) ESR1ESR2LMNAMEN1MAPT
SCHEMBL6009933 0.90 ESR1 (1.00) ESR1ESR2LMNAMEN1MAPT
SCHEMBL224399 0.90 ESR1 (1.00) ESR1ESR2LMNAMEN1MAPT
SCHEMBL12027477 0.90 ESR1 (1.00) ESR1ESR2LMNAMEN1MAPT
SCHEMBL11490000 0.88 ESR1 (0.82) ESR1ESR2LMNAMEN1MAPT
SCHEMBL5497281 0.88 ESR1 (0.82) ESR1ESR2LMNAMEN1MAPT
SCHEMBL5497284 0.88 ESR1 (0.82) ESR1ESR2LMNAMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014131891-A1 USE OF FETUIN-B FOR CULTURE OF OOCYTES Rheinisch-Westfälische Technische Hochschule Aachen (DE) 2014-09-04 — — WO claimed
WO-2014131891-A1 USE OF FETUIN-B FOR CULTURE OF OOCYTES Rheinisch-Westfälische Technische Hochschule Aachen (DE) 2014-09-04 — — WO disclosed
US-20070275935-A1 Estratriene Derivatives CRYPTOPHARMA PTY LTD (AU) 2007-11-29 — — US disclosed
CN-1867577-A Estratriene derivatives CRYPTOPHARMA PTY LTD (AU) 2006-11-22 — — CN disclosed
US-6465005-B1 STEROID AS A CRYSTALLIZATION INHIBITOR DURING STORAGE; INHIBITOR SELECTED FROM AN ESTROGEN, A PROGESTOGEN, AN ANDROGEN AND A GLUCOCORTICOID AMARIN TECHNOLOGIES S.A. (AR) 2002-10-15 — — US disclosed
EP-1023055-B1 INHIBITION OF CRYSTALLIZATION IN TRANSDERMAL DEVICES AMARIN TECHNOLOGIES S A (AR) 2002-01-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275935-A1 Estratriene Derivatives ESR2, ESRRB, NR3C2 ESR1 5/4885ESR2 1/4885LMNA 3831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.